| Exclusion Criteria: | 1) Are unable to swallow tablets.
2) Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
3) Are unable to discontinue use of enzyme inducing anti-epileptic drugs (EIAEDs), such as phenytoin, carbamazepine, or phenobarbital.
4) Have a prior malignancy (other than CRC or adequately treated carcinoma in situ of the cervix or nonmelanoma skin cancer), unless that prior malignancy was diagnosed and definitively treated at least 5 years previously with no subsequent evidence of recurrence.
5) Are pregnant or lactating.
6) Are receiving concurrent administration of any other antitumor therapy.
7) Have known hypersensitivity to any component of enzastaurin.
8) Have a serious concomitant systemic disorder (for example, active infection including known HIV) that, in the opinion of the investigator, would compromise the patient's ability to adhere to the protocol.
9) Have a serious cardiac condition, such as myocardial infarction within the last 6 months, angina, unstable coronary artery disease, known arterial thrombosis, or heart disease, as defined by the New York Heart Association Class II, III or IV.
10) Have known central nervous system metastases. A screening CT or MRI before enrollment in the absence of a clinical suspicion of brain metastases is not required.
11) Have inadequately controlled hypertension (defined as systolic blood pressure >140 and/or diastolic >90 mm Hg on antihypertensive medications).
12) Have any prior history of hypertensive crisis or hypertensive encephalopathy.
13) Have evidence of bleeding diathesis or coagulopathy.
14) Have had major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to randomization or have an anticipated need for major surgery during the course of the study.
15) Have had a core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment.
16) Have a serious, nonhealing wound, ulcer, or bone fracture.
17) Have a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study entry.
18) History of stroke or transient ischemic attack within 6 months prior to randomization.
19) Have significant vascular disease (such as aortic aneurysm or aortic dissection) or symptomatic peripheral vascular disease.
20) Have proteinuria at baseline, as demonstrated by either: 1) urine dipstick for proteinuria =/>2+. Patients discovered to have =/>2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate =/<1 g of protein in 24 hours to be eligible. 2) urine protein:creatinine (UPC) ratio =/>1.0 at baseline. |